Pacira Biosciences' Exparel Patent Status
Pacira Biosciences' drug Exparel (bupivacaine liposome injectable suspension) is covered by several patents that influence its market exclusivity. DrugPatentWatch.com tracks these patents and their implications for generic competition [1].
When Does Exparel's Main Patent Expire?
The primary patent protecting Exparel, U.S. Patent No. 7,772,207, is set to expire on December 23, 2024 [2]. This expiration date is crucial as it signals the potential for generic versions of Exparel to enter the market.
Are There Other Patents Protecting Exparel?
In addition to U.S. Patent No. 7,772,207, Pacira Biosciences holds other patents related to Exparel's formulation and manufacturing processes. These secondary patents can extend market protection beyond the expiration of the primary patent [1]. The specific expiration dates and coverage of these additional patents are detailed on platforms like DrugPatentWatch.com.
What Happens When Patents Expire?
Upon patent expiration, other pharmaceutical companies may seek to market generic versions of Exparel. This typically leads to increased competition and often results in lower prices for the medication. However, the entry of generics can be influenced by various factors, including the strength of remaining patents and any potential legal challenges [1].
Why Might Companies Challenge Exparel's Patents?
Companies interested in producing generic versions of Exparel may challenge its existing patents. These challenges often aim to invalidate or work around existing patent claims, thereby accelerating the timeline for generic market entry. Such legal strategies are common in the pharmaceutical industry to gain early access to lucrative markets.
How is Exparel Used?
Exparel is an injectable, non-opioid, local anesthetic that provides post-surgical pain relief. It is administered as a single dose in the field of surgery to desensitize nerve endings, offering pain management for up to 72 hours post-operation [3].
What is the Market Impact of Exparel's Patent Expirations?
The expiration of Exparel's patents is anticipated to open the door for generic competition. This could significantly alter the market landscape, potentially increasing patient access to the drug and reducing healthcare costs associated with pain management. DrugPatentWatch.com provides insights into these market dynamics [1].
Sources:
[1] DrugPatentWatch.com: https://drugpatentwatch.com/
[2] U.S. Patent No. 7,772,207
[3] Pacira Biosciences Patient Information